Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing MATRix as remission induction in PCNSL
DRKS00022768Phase 3Active, not recruiting
- Sponsor
- Klinikum Stuttgart
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of rituximab, methotrexate, cytarabine, thiotepa and carmustine in primary central nervous system lymphoma (PCNSL), diffuse large B-cell lymphoma (DLBCL), brain cancer and 1 more (2 arms), sponsored by Klinikum Stuttgart. Started Jun 2021; status: active, not recruiting.
02
Drugs
rituximabmethotrexatecytarabinethiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)brain cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on DRKS00022768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00022768.